Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors.

Autor:	Nasir Z; Radiology, Altnagelvin Area Hospital, Londonderry, GBR., Mahmood T; Radiology, Jinnah Post Graduate Medical Centre, Karachi, PAK., Adel H; Radiology, Dow University of Health Sciences, Karachi, PAK., Nausheen S; Radiology, Jinnah Postgraduate Medical Center, Karachi, PAK., Hamid S; Radiology, Jinnah Postgraduate Medical Center, Karachi, PAK., Sattar A; Radiology, Dow University of Health Sciences, Karachi, PAK., Manohar M; Radiology, Dow University of Health Sciences, Karachi, PAK.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2019 Aug 18; Vol. 11 (8), pp. e5422. Date of Electronic Publication: 2019 Aug 18.
DOI:	10.7759/cureus.5422
Abstrakt:	Introduction Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) is used for non-invasive staging and restaging of solid malignant tumors. PET-CT based criteria have been developed to evaluate the response to targeted therapy. These include the European Organization for Research and Treatment of Cancer (EORTC) and the PET Response Criteria in Solid Tumors (PERCIST). The aim of this study was to determine the agreement between EORTC and PERCIST criteria for treatment response evaluation in patients with solid malignant tumors. Materials and methods This was a retrospective study conducted from February 2017 till July 2017. Electronic medical records of patients diagnosed with solid malignant tumors were searched. Experienced radiologists evaluated the PET-CT images based on EORTC and PERCIST criteria. The Kappa (κ) test was used for evaluation of agreement between treatment response according to EORTC and PERCIST criteria. Results Out of 54 patients, 41 (75.9%) were male and 13 (24.1%) were female with a mean age of 57.09 ± 10.65 years. According to EORTC criteria, complete metabolic response (CMR) was seen in five (9.3%) of patients, partial metabolic response (PMR) was seen in 36 (66.7%) of patients, progressive metabolic disease (PMD) was seen in nine (16.7%) of patients and stable metabolic disease (SMD) was seen in four (7.4%) of patients. According to PERCIST criteria, CMR was seen in five (9.3%) of patients, PMR was seen in 33 (61.1%) of patients, PMD was seen in nine (16.7%) of patients and SMD was seen in seven (13.0%) of patients. EORTC and PERCIST agreed on 43 (79.6%) of the patients with κ-coefficient of 0.62 indicating good agreement (p-value of <0.001). Conclusion EORTC and PERCIST criteria have a good agreement in evaluating treatment response in solid malignant tumors. Therefore, adoption of EORTC or PERCIST in PET-CT reporting can standardize the evaluation of oncological treatment results. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2019, Nasir et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu